SIMULTANEOUS SUBMISSION OF GENE THERAPY PROTOCOLS TO FDA, NIH ON RAC AGENDA
Executive Summary
The simultaneous submission of protocols for gene therapy treatments to FDA and the National Institutes of Health will be considered by the NIH Recombinant DNA Advisory Committee as part of proposed consolidated review procedures at its March 6-7 meeting in Bethesda, Md.